We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
-$168M
Cap. Flow %
-36.97%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Healthcare 21.24%
2 Technology 0.34%
3 Consumer Staples 0.21%
4 Financials 0.17%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
26
CALL
Nektar Therapeutics
NKTR
$2.39B
$2.14M 0.47%
43
+4
+10% +$2.42K
KYNB
27
Kyntra Bio
KYNB
$28.2M
$2.1M 0.46%
1,817
+1,336
+278% +$1.5M
COGT icon
28
Cogent Biosciences
COGT
$6.95B
$1.97M 0.43%
111,704
-23,651
-17% -$700K
MDGL icon
29
CALL
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.74M 0.38%
154
– –
AVEO
30
CALL
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.72M 0.38%
1,073
-145
-12% -$3.19K
OTLK icon
31
Outlook Therapeutics
OTLK
$169M
$1.39M 0.31%
17,415
-3,553
-17% -$437K
PAVMZ
32
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$1.25M 0.28%
3,923,204
+1,976,366
+102% +$663K
AMRN
33
Amarin Corp
AMRN
$293M
$1.16M 0.25%
+4,252
New +$1.55M
SGMO
34
PUT
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$946K 0.21%
824
-2,274
-73% -$28.2K
SGMO
35
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$932K 0.21%
81,161
-75,752
-48% -$941K
GNPX icon
36
Genprex
GNPX
$4.05M
$915K 0.2%
19
+2
+12% +$132K
SLNO
37
DELISTED
Soleno Therapeutics
SLNO
$906K 0.2%
35,328
-15,026
-30% -$439K
BIIB icon
38
CALL
Biogen
BIIB
$30.4B
$903K 0.2%
+30
New +$9.57K
CYTR
39
DELISTED
CytRx Corp
CYTR
$833K 0.18%
1,855,879
+586,148
+46% +$405K
ABIL
40
DELISTED
Ability Inc
ABIL
$680K 0.15%
+357,974
New +$1.02M
CATX icon
41
Perspective Therapeutics
CATX
$327M
$676K 0.15%
225,483
+32,934
+17% +$141K
TNXP icon
42
Tonix Pharmaceuticals
TNXP
$158M
– –
0
– –
AQB icon
43
AquaBounty Technologies
AQB
$4.74M
$649K 0.14%
+15,833
New +$818K
TOVX icon
44
Theriva Biologics
TOVX
$9.8M
$626K 0.14%
+4,470
New +$1.06M
NXTP
45
DELISTED
NextPlay Technologies, Inc. Common Stock
NXTP
$613K 0.13%
25,521
+3,292
+15% +$96.3K
DNTH icon
46
Dianthus Therapeutics
DNTH
$5.55B
$611K 0.13%
6,697
+808
+14% +$110K
LFWD icon
47
ReWalk Robotics
LFWD
$19.6M
$569K 0.13%
+1,556
New +$1.65M
VKTX icon
48
Viking Therapeutics
VKTX
$3.93B
$555K 0.12%
72,500
-90,963
-56% -$1.09M
MDGSW
49
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$522K 0.11%
1,043,764
-224,382
-18% -$153K
PHIO icon
50
Phio Pharmaceuticals
PHIO
$11.7M
$520K 0.11%
+265
New +$626K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management withdrew a net $168M in Q4 2018, closing 40 positions and reducing 40 holdings. Its most notable exit was Amicus Therapeutics, an estimated $1.87M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in State Street SPDR S&P Biotech ETF worth $4.47M.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.